Biofourmis Raises Additional Funding From Intel Capital In Series D Extension And Names Top Healthcare Leaders To Its Board
Biofourmis Raises Additional Funding From Intel Capital In Series D Extension And Names Top Healthcare Leaders To Its Board
08/10/22, 11:35 AM
Location
bostonIndustry
data and analytics
health care
software
Round Type
series d
Biofourmis, a Boston-based global leader in virtual care and digital medicine, today announced that Intel Capital, the strategic investment arm of chipmaker Intel Corporation, has joined its Series D financing in an extension that brings the total funding raised in the round to $320M. The initial Series D funding round was announced in April and was led by global growth equity firm General Atlantic with participation by CVS Health (NYSE:CVS), Trevor Fetter and existing investors.
Company Info
Location
boston, massachusetts, united states
Additional Info
Biofourmis, based in Boston, is a global leader in providing advanced technology and clinical support for [email protected] and digital therapies. We are driven by a passion to personalize care and predict clinical worsening before it happens. Our clinically validated platform, powered by machine learning and advanced analytics, enables better healthcare, maximizes the effectiveness of high-value drugs, and lowers costs across the entire care continuum. For more information, visit www.biofourmis.com and follow us on LinkedIn, Twitter and YouTube.